Figure 2. SPARCL1 expression profiles in human prostate.

(A) Prostate protein samples were derived from benign human prostate tissue and high-grade CaP specimens. SPARCL1 expression was measured using Western Blot (upper panel), and total protein amounts were examined by re-probing with anti-β-actin (middle panel). Western blot results were quantified by densitometry. Normalized fold changes of SPARCL1 expression between each CaP sample and non-malignant sample were deduced (fold change values) and listed beneath the SPARCL1 bands (bottom panel). Note that CaP samples expressed lower levels of endogenous SPARCL1 than non-malignant prostate samples.

(B) Evaluations of SPARCL1 expression profiles in human CaP cell lines. A Western blot was used to measure differential expression of SPARCL1 among several CaP cell lines. Cell lysate samples included benign human prostate tissue and cell lines (NHPrE1/BHPrE1) and various CaP cell lines (LNCaP, ARCaPM, and PC3). The Western blot membrane was re-probed with anti-β-actin. The SPARCL1 fold changes were derived from the ratios to β-actin expression within each cell line and were further normalized by the ratio from the normal prostate sample.